XDH and metabolic dysfunction-associated steatohepatitis: While both XO inhibitors demonstrated comparable effects in lowering UA levels in the bloodstream, febuxostat exhibited a significant reduction in hepatic UA levels and XO activity in a NASH model in mice, a response not observed with allopurinol (116).